Vicki Moore, PhD

Contributing Writer https://www.hematologyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

Patients with splanchnic vein thrombosis may be at an increased risk for bleeding.

Thrombotic Disorders

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms

By

Vicki Moore, PhD

December 6, 2019

Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.

A doctor speaks to an elderly patient.

Type 2 Diabetes Mellitus in Adult Survivors of Childhood Acute Lymphoblastic Leukemia

By

Vicki Moore, PhD

December 5, 2019

Older age, body mass index above 30, and development of drug-induced diabetes mellitus were associated with increased risk for type 2 diabetes mellitus.

DLBCL is a rare, B-cell non-Hodgkin’s lymphoma that affects older adults.

Polatuzumab Vedotin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

December 4, 2019

In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.

A hospital corridor.

Influence of Facility Patient Volume on Mortality in Classical Hodgkin Lymphoma

By

Vicki Moore, PhD

December 3, 2019

Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.

Multiple Myeloma

Outcomes With Plerixafor Following Autologous Stem Cell Transplantation for Multiple Myeloma

By

Vicki Moore, PhD

December 2, 2019

The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.

Two doctors consult over some files.

Thrombotic Disorders

Venous Thromboembolism Outcomes in Patients With Autoimmune Disorders

By

Vicki Moore, PhD

November 27, 2019

Researchers found no significant difference in venous thromboembolism recurrence rates between patients with and without autoimmune disorders.

A woman speaks with her doctor.

Bleeding Disorders

Severe Postpartum Hemorrhage as Evidence of an Inherited Bleeding Disorder

By

Vicki Moore, PhD

November 26, 2019

Of 69 patients referred for hemostatic examination due to severe postpartum hemorrhage, 16 (23%) were diagnosed with a mild bleeding disorder.

Leukemia blast cells

Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia

By

Vicki Moore, PhD

November 25, 2019

Among patients treated with an acute lymphoblastic leukemia induction regimen, 72% achieved end-of-induction complete remission.

Researchers conducted a meta-analysis of 4 studies examining prophylaxis with factor VIII or emicizumab for hemophilia A without inhibitors.

Hematopoietic Score for Risk Stratification of Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

November 22, 2019

Researchers developed and tested a risk stratification model based on hematopoietic variables that can be obtained from a complete blood count.

Patients who experienced an iron chelation response had lower transfusion burden and substantial decrease in ferritin values.

Improving Bone Mass With Iron Chelation Therapy in Transfusion-Dependent Beta Thalassemia

By

Vicki Moore, PhD

November 21, 2019

Iron chelation therapy with deferasirox and deferoxamine led to significant improvements in bone mineral density and serum ferritin levels.